relative to prescription drug affordability board conflicts of interest.

Introduced

In Committee

Floor

Crossed Over

Passed

Enacted

Overview Bill text 1 History 10 Sponsors 2

Oct 31, 2024 · House

Interim Study Report: Not Recommended for Future Legislation (Vote 16-0)

Sep 25, 2024 · House

Executive Session: 10/17/2024 10:00 am LOB 302-304

Aug 14, 2024 · House

Full Committee Subcommittee Work Session: 09/12/2024 10:00 am LOB 302-304

Mar 28, 2024 · House

Refer for Interim Study: MA VV 03/28/2024 HJ 10 P. 7

Mar 18, 2024 · House

Committee Report: Refer for Interim Study 03/13/2024 (Vote 18-0; CC) HC 12 P. 6

Mar 7, 2024 · House

Executive Session: 03/13/2024 10:00 am LOB 302-304

Feb 14, 2024 · House

Subcommittee Work Session: 02/20/2024 10:00 am LOB 305

Feb 7, 2024 · House

Subcommittee Work Session: 02/14/2024 10:00 am LOB 302-304

Jan 9, 2024 · House

Public Hearing: 01/18/2024 10:15 am LOB 302-304

Dec 1, 2023 · House

Introduced 01/03/2024 and referred to Commerce and Consumer Affairs

PASSAGE PROBABILITY

6.9% Unlikely

Why this number

Stage base In Committee — base rate 27%, measured from NH's completed sessions
Momentum -4 33/100 from the pace of recorded action
Time since last action -22 709 days quiet
Cosponsors +1 1 signed on
Sponsor influence +5 95/100

A transparent scoring model over stage, momentum, recency, sponsorship and recorded votes — not a trained predictor. Treat it as a way to rank attention, not as a forecast.